Kairos Pharma (KAPA) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing therapeutics to overcome immune suppression and drug resistance in cancer, with a portfolio of seven drug candidates targeting prostate, lung, breast cancer, and glioblastoma.

• Lead programs include ENV 105 (antibody targeting CD105/Endoglin) in Phase 2 for prostate cancer and Phase 1 for lung cancer, and KROS 101 (GITR ligand modulator) in preclinical development.

• Technologies are licensed from Cedars-Sinai Medical Center and Tracon Pharmaceuticals, with a strategy to leverage academic partnerships and virtual operations for capital efficiency.

Financial performance and metrics

• For the nine months ended September 30, 2024, reported a net loss of $1.6 million, with an accumulated deficit of $7.8 million as of that date.

• Cash on hand was $3.2 million at September 30, 2024, with working capital of $3.1 million and total assets of $5.0 million.

• Operating expenses for the nine months ended September 30, 2024, were $897,000, primarily driven by increased R&D for clinical trial initiation.

• IPO in September 2024 raised $6.2 million in gross proceeds, with additional PIPE financing of $3.5 million in January 2025.

Use of proceeds and capital allocation

• Proceeds from warrant exercises (up to $5.5 million if fully exercised) will fund ongoing Phase 1 and 2 clinical trials, preclinical development, potential acquisitions or in-licensing, and general corporate purposes.

• Recent NIH grant of $3.2 million awarded to support biomarker development and corollary studies for ENV 105 Phase 2 trial, with funds managed by Cedars-Sinai.

• Equity line of credit agreement with Helena Global for up to $30 million in additional capital, available upon registration of shares.